The metabolism of Finasteride can be decreased when combined with Erythromycin. The metabolism of Cocaine can be decreased when combined with Erythromycin. The metabolism of Cyclosporine can be decreased when combined with Butoconazole. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol. The therapeutic efficacy of Linagliptin can be decreased when used in combination with Brexpiprazole. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gepirone. The risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine. The serum concentration of Levonorgestrel can be decreased when it is combined with Fosaprepitant. The serum concentration of Lynestrenol can be decreased when it is combined with Griseofulvin. The risk or severity of adverse effects can be increased when Diclofenac is combined with Parecoxib. Indomethacin may decrease the excretion rate of GPX-150 which could result in a higher serum level. The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxyphenbutazone. The risk or severity of adverse effects can be increased when Posaconazole is combined with Xylometazoline. Tinoridine may decrease the antihypertensive activities of Bisoprolol. Adapalene may increase the nephrotoxic activities of Cyclosporine. The risk or severity of adverse effects can be increased when Ketazolam is combined with Levodopa. Phenylbutazone may increase the neuroexcitatory activities of Sparfloxacin. The metabolism of Gavestinel can be decreased when combined with Sulfisoxazole. The therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide. Ethanol can cause an increase in the absorption of Treprostinil resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Apocynin is combined with Desonide. The risk or severity of adverse effects can be increased when Clobetasone is combined with BCG vaccine. The serum concentration of Sisomicin can be decreased when it is combined with Azlocillin. The risk or severity of adverse effects can be increased when Ketorolac is combined with Phenylbutazone. The metabolism of Ketoprofen can be decreased when combined with Delavirdine. Yohimbine may decrease the antihypertensive activities of Losartan. The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone. The serum concentration of Desonide can be increased when it is combined with Saquinavir. The therapeutic efficacy of Linagliptin can be decreased when used in combination with Norgestimate. Certoparin may increase the hyperkalemic activities of Telmisartan. The therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin. The metabolism of Icotinib can be increased when combined with Pentobarbital. The risk or severity of adverse effects can be increased when Ketorolac is combined with Carprofen. The risk or severity of adverse effects can be increased when Tacrolimus is combined with Epirubicin. The metabolism of Oxaprozin can be decreased when combined with Irbesartan. The therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium Hydroxide. The metabolism of Famciclovir can be decreased when combined with Isradipine. The serum concentration of Desogestrel can be decreased when it is combined with Lopinavir. The metabolism of Nateglinide can be decreased when combined with Irbesartan. Polythiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level. The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brompheniramine. Tiotropium may increase the anticholinergic activities of Sulpiride. The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levodopa. Suprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Hydrocodone is combined with Quinethazone. The serum concentration of Dexamethasone can be decreased when it is combined with Phenytoin. The metabolism of Tetrabenazine can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorphenamine. The metabolism of Diclofenac can be decreased when combined with Rucaparib. The metabolism of Desvenlafaxine can be decreased when combined with Clemastine. Isoetarine may increase the hypokalemic activities of Hydrochlorothiazide. Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Oxybutynin may increase the anticholinergic activities of Umeclidinium. The risk or severity of adverse effects can be increased when Melperone is combined with Methocarbamol. The risk or severity of adverse effects can be increased when Quinapril is combined with Duvelisib. The risk or severity of adverse effects can be increased when Benzocaine is combined with Allopregnanolone. The risk or severity of adverse effects can be increased when Tropicamide is combined with Pentazocine. The risk or severity of adverse effects can be increased when Opium is combined with Mebanazine. The risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine. Brimonidine may increase the antihypertensive activities of Dihydralazine. The risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorzoxazone. The therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine. The serum concentration of Disopyramide can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Amphotericin B is combined with Streptokinase. The risk or severity of adverse effects can be increased when Amobarbital is combined with Dextropropoxyphene. The metabolism of Lisuride can be increased when combined with Pentobarbital. The metabolism of Salicylic acid can be decreased when combined with Sulfamethoxazole. The metabolism of Cinnarizine can be decreased when combined with Clobazam. The risk or severity of adverse effects can be increased when Amobarbital is combined with Efavirenz. Indobufen may decrease the antihypertensive activities of Metipranolol. Octamoxin may increase the hypotensive activities of Timolol. Isocarboxazid may increase the hypotensive activities of Perindopril. The metabolism of Indacaterol can be decreased when combined with Boceprevir. The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenbufen. The metabolism of Esmirtazapine can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Telmisartan is combined with Nifedipine. The risk or severity of adverse effects can be increased when Oxprenolol is combined with Methocarbamol. The therapeutic efficacy of Buformin can be decreased when used in combination with Hydroflumethiazide. The metabolism of Dapagliflozin can be decreased when combined with Clobazam. Udenafil may increase the antihypertensive activities of Timolol. The serum concentration of Phenprocoumon can be decreased when it is combined with Ethanol. The metabolism of Isosorbide Dinitrate can be decreased when combined with Sulfisoxazole. The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast. The risk or severity of adverse effects can be increased when Bromfenac is combined with Naproxen. Venlafaxine may increase the hyponatremic activities of Metolazone. E-6201 may decrease the diuretic activities of Bumetanide. The risk or severity of adverse effects can be increased when Prednisolone is combined with Prulifloxacin. Betaxolol may increase the hypotensive activities of Mibefradil. The serum concentration of Trichlormethiazide can be increased when it is combined with Darifenacin. The risk or severity of adverse effects can be increased when Temazepam is combined with Levocabastine. The serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide. Scopolamine may increase the anticholinergic activities of Aclidinium. Sulfasalazine may increase the nephrotoxic activities of Tacrolimus. Formestane may increase the hypokalemic activities of Chlorothiazide. The therapeutic efficacy of Metolazone can be decreased when used in combination with Benoxaprofen. The serum concentration of Amitriptyline can be increased when it is combined with Cilazapril. The serum concentration of Ubidecarenone can be increased when it is combined with Darunavir. The serum concentration of Ulipristal can be increased when it is combined with Simeprevir. The metabolism of Clopidogrel can be decreased when combined with Pyrimethamine. The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydroflumethiazide. The serum concentration of Ketobemidone can be increased when it is combined with Ivacaftor. Diclofenac may decrease the excretion rate of Apramycin which could result in a higher serum level. The metabolism of Efavirenz can be decreased when combined with Rucaparib. Moexipril may increase the orthostatic hypotensive activities of Levodopa. The metabolism of Estrone sulfate can be increased when combined with Pentobarbital. The therapeutic efficacy of Exenatide can be decreased when used in combination with Dienogest. The risk or severity of adverse effects can be increased when Streptokinase is combined with Papaverine. The risk or severity of adverse effects can be increased when Procyclidine is combined with Fentanyl. Amphetamine may increase the hypotensive activities of Valsartan. The therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam. The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxyphenbutazone. The risk or severity of adverse effects can be increased when Lorazepam is combined with Methylecgonine. Adapalene may decrease the antihypertensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Propoxycaine is combined with Dexbrompheniramine. The risk or severity of adverse effects can be increased when Cyclizine is combined with Levocetirizine. Benazepril may increase the hypotensive activities of Cryptenamine. The therapeutic efficacy of Tropicamide can be decreased when used in combination with Distigmine. The serum concentration of Finasteride can be decreased when it is combined with Dabrafenib. The serum concentration of Tamsulosin can be increased when it is combined with Posaconazole. Perindopril may increase the hypotensive activities of Ferulic acid. The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Bifonazole. The serum concentration of Paritaprevir can be increased when it is combined with Stiripentol. Cilazapril may increase the hypotensive activities of BQ-123. The metabolism of Lisuride can be decreased when combined with Saquinavir. Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Nadolol. The risk or severity of adverse effects can be increased when Azapropazone is combined with Desonide. The serum concentration of Fentanyl can be increased when it is combined with Sulfisoxazole. The metabolism of Erythromycin can be decreased when combined with Cobicistat. The metabolism of Brompheniramine can be decreased when combined with Lovastatin. Aluminum hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.